Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2026

Description

Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that employs engineered RNA viruses to specifically target and destroy tumor cells. These viruses multiply within cancer cells, leading to their elimination and the release of tumor antigens. This process also activates the immune system to identify and attack any remaining cancer cells, improving overall anti-tumor effectiveness.

The primary therapy types of ribonucleic acid (RNA)-based oncolytic therapy include messenger ribonucleic acid (mRNA)-based oncolytic therapy, small interfering ribonucleic acid (siRNA)-based oncolytic therapy, micro ribonucleic acid (miRNA)-based oncolytic therapy, and other therapy types. Messenger ribonucleic acid (mRNA)-based oncolytic therapy involves the use of synthetic mRNA molecules designed to stimulate the immune system or directly trigger tumor cell death, providing a targeted and flexible approach to cancer treatment. These therapies are delivered via routes such as intravenous, intratumoral, and other methods, and are used in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. The main end-users include hospitals, cancer research institutes, specialty clinics, and others.

Tariffs are influencing the RNA-based oncolytic therapy market by increasing costs of imported nucleic acids, viral vectors, lipid nanoparticles, bioprocessing equipment, and cold-chain logistics systems. Cancer research institutes and hospitals in North America and Europe are most affected due to reliance on imported high-purity RNA materials, while Asia-Pacific faces higher costs in advanced therapy manufacturing. These tariffs are increasing development and trial costs and extending commercialization timelines. At the same time, they are encouraging domestic biomanufacturing, regional sourcing of RNA components, and investment in local advanced therapy production capabilities.

The ribonucleic acid (rna)-based oncolytic therapy market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna)-based oncolytic therapy market statistics, including ribonucleic acid (rna)-based oncolytic therapy industry global market size, regional shares, competitors with a ribonucleic acid (rna)-based oncolytic therapy market share, detailed ribonucleic acid (rna)-based oncolytic therapy market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna)-based oncolytic therapy industry. This ribonucleic acid (rna)-based oncolytic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ribonucleic acid (rna)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $2.12 billion in 2025 to $2.51 billion in 2026 at a compound annual growth rate (CAGR) of 18.7%. The growth in the historic period can be attributed to advancements in cancer virology research, increasing understanding of tumor immunology, availability of clinical trial infrastructure, rising oncology research funding, early success of oncolytic virus studies.

The ribonucleic acid (rna)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.94 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing approvals of rna-based cancer therapies, rising demand for personalized oncology treatments, expansion of immuno-oncology pipelines, growing investment in gene and cell therapies, technological advancements in rna delivery systems. Major trends in the forecast period include increasing advancement of rna virus engineering, rising adoption of combination oncolytic therapies, growing focus on immune system activation, expansion of targeted tumor-specific rna therapies, enhanced integration of precision oncology tools.

The increasing adoption of personalized medicine is anticipated to drive the growth of the RNA-based oncolytic therapy market in the coming years. Personalized medicine refers to treatments designed according to an individual's genetic profile, enhancing effectiveness and minimizing side effects. The use of personalized medicine is rising as more healthcare providers and institutions acknowledge its potential to improve patient outcomes through targeted therapies and precision diagnostics. RNA-based oncolytic therapy is pivotal in cancer care, supporting the adoption of personalized medicine by providing targeted, patient-specific treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy organization for tailored medical treatments, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared to 6 in 2022. Thus, the expanding adoption of personalized medicine is propelling the RNA-based oncolytic therapy market.

Major companies are active in the ribonucleic acid (RNA)-based oncolytic therapy market, concentrating on developing technological innovations such as synthetic messenger RNA (mRNA) technology to improve tumor-targeting efficiency, enhance immune response, and achieve more precise and long-lasting cancer treatment outcomes. Synthetic messenger RNA (mRNA) technology is a biotechnology method that creates and delivers lab-designed mRNA sequences to instruct cells to produce specific therapeutic proteins for disease management, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a China-based pharmaceutical company, obtained regulatory approval in China to begin clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This milestone marks a significant advancement in the nation's messenger RNA therapeutics field. SYS6020 uses mRNA-lipid nanoparticle technology to selectively target and destroy myeloma cancer cells with minimal side effects, while also showing potential for treating certain autoimmune disorders.

In June 2023, Charles River Laboratories International, Inc., a US-based contract research organization (CRO), teamed up with Curigin Co., Ltd. to develop oncolytic RNAi gene therapy. Through this partnership, the goal is to accelerate the development and production of Curigin's RNAi-based oncolytic gene therapies by drawing on Charles River's CDMO expertise to aid preclinical and clinical trials. Curigin Co. Ltd. is a South Korea-based biotechnology company focused on creating RNA interference (RNAi)-based oncolytic gene therapies for cancer treatment.

Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (rna)-based oncolytic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ribonucleic acid (rna)-based oncolytic therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid (rna)-based oncolytic therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna)-based oncolytic therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy; Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy; Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy; Other Therapy Types
2) By Route Of Administration: Intravenous; Intratumoral; Other Route Of Administrations
3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Other Applications
4) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA); Non-Replicating mRNA; Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA; Nanoparticle-Delivered siRNA; Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics; miRNA Inhibitors (Antagomirs); miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies; Short Hairpin RNA (shRNA)-Based Therapies; Aptamer-RNA Based Oncolytic Agents
Companies Mentioned: AstraZeneca PLC; Moderna Inc.; BioNTech SE; Gritstone Bio Inc.; Orna Therapeutics Inc.; Strand Therapeutics Inc.; Oncolytics Biotech Inc.; Anima Biotech Inc.; eTheRNA immunotherapies NV; Vyriad Inc.; Haya Therapeutics Inc.; Virogin Biotech Inc.; Providence Therapeutics Holdings Inc.; Sirnaomics Inc.; Humane Genomics Inc.; Replicate Bioscience Inc.; Abogen Biosciences Inc.; Chimeron Bio Inc.; Aro Biotherapeutics Inc.; TransCode Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MRARB01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Advancement Of RNA Virus Engineering
- 4.2.2 Rising Adoption Of Combination Oncolytic Therapies
- 4.2.3 Growing Focus On Immune System Activation
- 4.2.4 Expansion Of Targeted Tumor-Specific RNA Therapies
- 4.2.5 Enhanced Integration Of Precision Oncology Tools

5. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Cancer Research Institutes
5.3 Specialty Oncology Clinics
5.4 Academic Research Centers
5.5 Biopharmaceutical Companies

6. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmentation

9.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types
9.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intravenous, Intratumoral, Other Route Of Administrations
9.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications
9.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users
9.5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy
9.6. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA
9.7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys
9.8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents

10. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional And Country Analysis

10.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

11.1. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

12.1. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

13.1. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

14.1. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

15.1. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

16.1. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

17.1. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

18.1. Taiwan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

19.1. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

20.1. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

21.1. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

22.1. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

23.1. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

24.1. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

25.1. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

26.1. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

27.1. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

28.1. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

29.1. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

30.1. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

31.1. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

32.1. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

33.1. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

34.1. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Segmentation By Route Of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regulatory and Investment Landscape

36. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Landscape And Company Profiles

36.1. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Company Profiles
- 36.3.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Gritstone Bio Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Orna Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Other Major And Innovative Companies

Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

38. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

40. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market High Potential Countries, Segments and Strategies

40.1 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2030 - Countries Offering Most New Opportunities
40.2 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2030 - Segments Offering Most New Opportunities
40.3 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer